

This is a repository copy of *Identifying primary care indicators for people with serious mental illness : a systematic review*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/118746/>

Version: Accepted Version

---

**Article:**

Kronenberg, Christoph, Doran, T. [orcid.org/0000-0001-7857-3704](https://orcid.org/0000-0001-7857-3704), Goddard, M. [orcid.org/0000-0002-1517-7461](https://orcid.org/0000-0002-1517-7461) et al. (5 more authors) (2017) Identifying primary care indicators for people with serious mental illness : a systematic review. British Journal of General Practice. ISSN 0960-1643

<https://doi.org/10.3399/bjgp17X691721>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

# QUALITY INDICATORS FOR PRIMARY CARE OF PEOPLE WITH SERIOUS MENTAL ILLNESS: A SYSTEMATIC REVIEW

Accepted on 8 March 2017 for publication in the British Journal of General Practice.

Christoph Kronenberg, MSc, CINCH - National Research Center for Health Economics, University of  
Duisburg-Essen, Essen, Germany

Tim Doran, MD MPH MFPH, Department of Health Sciences, University of York, Heslington, York, UK

Maria Goddard, MSc, Centre for Health Economics, University of York, Heslington, York, UK

Tony Kendrick, MD FRCGP FRCPsych, Primary Care and Population Sciences, University of  
Southampton, Southampton, UK

Simon Gilbody, DPhil FRCPsych, Department of Health Sciences, University of York, Heslington, York,  
UK

Ceri R Dare, Service User, UK

Lauren Aylott, Service User, UK

\*Rowena Jacobs, PhD, Centre for Health Economics, University of York, Heslington, York, UK

\*Correspondence: [rowena.jacobs@york.ac.uk](mailto:rowena.jacobs@york.ac.uk), Tel: +44(0)1904 3214125, Fax: +44(0)1904 321402

## **Conflict of interest**

The authors declare that they have no competing interests.

**Word count:** 2617 (for the text excluding title page, abstract, references, tables and figures).

**Numbers of tables:** 2

**Numbers of figures:** 1

**Numbers of appendices:** 2

# Quality Indicators for Primary Care of People with Serious Mental Illness: A Systematic Review

Christoph Kronenberg, Tim Doran, Maria Goddard, Tony Kendrick,  
Simon Gilbody, Ceri Dare, Lauren Aylott, Rowena Jacobs

## Abstract

**Background** – Serious mental illness (SMI) – which comprises long term conditions such as schizophrenia, bipolar disorder and other psychoses – has enormous costs for both patients and society. In many countries, people with SMI are treated solely in primary care, and have particular needs for physical care.

**Aim** - The objective of this study was to review systematically the literature to create a list of quality indicators relevant to patients with SMI which could be captured using routine data, and which could be used to monitor or incentivise better quality primary care.

**Design and setting** – A systematic literature review, combined with a search of quality indicator databases and guidelines.

**Methods** – We assessed whether indicators could be measured from routine data and the quality of the evidence.

**Results** – 1,847 papers and quality indicator databases were identified, 27 were included, from which 59 quality indicators were identified, covering six domains. Of the 59 indicators, 52 could be assessed using routine data. The evidence base underpinning these indicators was relatively weak, and was primarily based on expert opinion rather than trial evidence.

**Conclusions** – With appropriate adaptation for different contexts, and in line with relative responsibilities of primary and secondary care, use of the quality indicators has the potential to improve care and to improve the physical and mental health of people with SMI. However, before the indicators can be used to monitor or incentivise primary care quality, more robust links need to be established with improved patient outcomes.

(243/250 words)

**Keywords:** serious mental illness, primary care, quality indicators, pay-for-performance schemes

## How this fits in

This is a first systematic review of indicators of primary care quality for patients with serious mental illness (SMI). Our study identifies 59 quality indicators in six domains, the majority of which could be monitored using routine primary care data. A key domain is the focus on physical health care. Consideration of the use of a broad set of quality of care indicators may support the improvement of the mental and physical health for this patient group.

## Introduction

Serious mental illness (SMI) includes schizophrenia, bipolar disorder and other psychoses, (defined by International Classification of Diseases (ICD-10) <sup>1</sup> categories F20-F31, and including Schizophrenia Spectrum and Other Psychotic Disorders together with Bipolar and Related Disorders in DSM-5 <sup>2</sup>). SMI is linked with poor health outcomes, high healthcare costs and high disease burden <sup>3,4</sup>. People with SMI have on average a 20-year lower life expectancy, mostly due to preventable causes <sup>5-8</sup>. The global morbidity study attributed 3.5% of total Years Lost to Disability to schizophrenia and bipolar disorder combined <sup>9</sup>. SMI is also associated with increased treatment costs <sup>10</sup> and hospitalisations. Yet, around a third of people with SMI in the UK are treated solely in primary care <sup>11</sup> and are in long-term contact with primary care services more often than the general population <sup>12,13</sup>. Even in countries with very well developed secondary mental health care systems, primary care can make a key contribution to the care of people with SMI <sup>14</sup>. The quality of primary care of people with mental health problems is therefore of international concern <sup>15,16</sup>.

In the UK, a national pay-for-performance scheme, the Quality and Outcomes Framework (QOF), exists to financially reward family practices for achieving quality targets for patients with long term conditions. The SMI quality indicators in the QOF cover both mental health specific care (e.g. monitoring lithium levels) as well as more general physical care (e.g. routine health checks). QOF indicators are for high-priority disease areas for which primary care has principal responsibility for ongoing care, and where there is good evidence that improved primary care will have health benefits. However, the QOF may neglect important unmeasured aspects of quality of care <sup>17</sup>, and the incentives may result in tunnel vision <sup>18</sup> or a focus on activities which are prioritised at the expense of other non-incentivised activities <sup>19,20</sup>. For example, the QOF focuses more on physical rather than mental health, since this is generally easier to measure.

We performed a systematic review of the literature and interrogated international databases to identify potential quality indicators that could supplement or replace indicators already included in the QOF for people with SMI and which could potentially be incentivised in primary care. We included indicators that appeared in earlier versions of the QOF but were subsequently dropped from the scheme when it was reduced in scope to reduce workload. We have included these indicators on the grounds that they remain valid measures of quality of care, and continue to be included in the broader National Institute for Health and Care Excellence (NICE) indicators menu. A major focus of our analysis was the source of the data on which the indicators were based. Those requiring primary data collection, for example via surveys of patients or health professionals or retrospective auditing of patient records, would be very challenging to incorporate into incentive

schemes such as the QOF, whereas those based on routinely available data would in principle be more feasible to establish.

Previous literature reviews on quality indicators have focused on SMI in secondary care<sup>21,22</sup>, while our study is the first to focus specifically on people with SMI in primary care. Identifying indicators of primary care quality for people with SMI could help to strengthen the evidence base and shed light on neglected areas of care, as well as providing the basis for incentive schemes aimed at improving quality.

## Methods

A systematic review of primary care quality indicators for people with SMI was conducted with the aim of identifying quality indicators in addition to those already included in the QOF, either in the past or currently.

### **Inclusion and Exclusion Criteria**

We searched for published examples of potential quality indicators which could readily be collected in primary care with reference to routine data. Search terms were identified by an information specialist in conjunction with the project team. Included papers had the terms: serious mental illness AND primary care AND quality indicator, including alternative spellings and synonyms. Studies on children or covering non-psychotic illnesses e.g. severe depression or anxiety disorders were excluded. All studies from January 1990 to February 2015 were considered for inclusion. No language restrictions were applied, though all search terms were in English, and all studies in English, German, Dutch and Afrikaans were considered due to authors' language knowledge. The base search was constructed using MEDLINE and adapted to the other resources. The following databases were searched: Applied Social Sciences Index and Abstracts (ASSIA); CENTRAL, Cochrane Database of Systematic Reviews; Conference Proceedings Citation Index- Science (CPCI-S); Database of Abstracts of Reviews of Effects, DARE; EMBASE; Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations and Ovid MEDLINE(R); PsycINFO and MEDLINE. The full strategy for MEDLINE as a template is available in Appendix 1.

Additionally, previous reviews with overlapping aims were searched and we contacted authors to ask for their indicators (most notably Stegbauer et al<sup>21</sup> and Großimlinghaus et al<sup>23</sup>). The quality indicator database of the Agency for Healthcare Research and Quality (AHRQ)<sup>24</sup> was also searched for indicators relevant to primary care. The final selection of indicators was informed by the views of our Study Steering Committee, which included service users.

## **Study Selection**

Titles were first reviewed by MG, TK, TD, RJ and CK. All studies that two members of the research team indicated as potentially relevant were included in the abstract screening process. All abstracts were screened by LA, MG, TK, TD, RJ and CK, and full papers were obtained if two members of the team judged the abstract potentially relevant or in scope, i.e. covering serious mental illness, primary care and quality indicators. Full papers were divided into four groups and independently reviewed by MG & CO, TD & LA, TK & SG, and RJ & CK. The focus of the selection was to identify papers that included relevant quality indicators that could be applied in primary care. It was evident that the definition of primary care varies between different countries so we included indicators with elements of shared care between primary and specialist settings (e.g. prescribing and monitoring of antipsychotic medication), whilst acknowledging that in some countries, those indicators may be more applicable to secondary care.

Our search strategy complied with the PRISMA checklist (see Appendix 2).

## **Data Extraction and Analysis**

From each paper a short description of each indicator was extracted, and the descriptions for similar indicators were merged. After reviewing the general areas covered by the indicators, they were grouped into six domains: (Co-ordination of Care, Substance Misuse, Service Provision and Access to Care, Medicines Management, Mental Health Assessment and Care, and Physical Health Assessment and Care). The domains were selected by the research team, which included service users, as representing broad areas of service provision and care that were viewed as important and could encompass all the chosen indicators. Some of the indicators may overlap the domain description boundaries as they are not intended to be rigid boundaries. Given the main focus of our study, we decided whether each indicator could, in principle, be measured from routine data or whether primary data collection would be necessary. Furthermore, we checked whether the identified indicators had ever been included in the QOF. We also assessed the quality of the evidence of the included studies using an adaptation of the GRADE guidelines<sup>25</sup> and rated the quality of the evidence as high (systematic reviews or randomised control trials), moderate (non-randomised control studies or unsystematic reviews), low (expert opinion or uncontrolled studies) or not applicable (measure was extracted from the grey literature).

## **Results**

In total 1,847 studies and further database sources were identified using the search. The split was ASSIA (34), CENTRAL (96), Cochrane (12), Conferences Proceedings (125), DARE (28), EMBASE (738), Ovid Medline (537), PsycINFO (271) and 6 further database sources (AHRQ<sup>24</sup>, Stegbauer et al<sup>21</sup>,

Großimlinghaus et al <sup>23</sup>, Parameswaran et al <sup>22</sup>, and NICE <sup>26,27</sup>). After removing duplicates using bibliographic software (EndNote and Zotero), 1,303 records remained. Title screening reduced this to 356, excluding those that were not about quality indicators, or primary care, or mental illness, or were not included in our definition of SMI (e.g. depression or substance misuse disorders). Abstract screening reduced the records to 113, with similar reasons for exclusion. Finally, from those 113 records 86 were excluded, and 27 records were included in the review (see PRISMA flow diagram, Figure 1). Out of these 27 records, a final set of 59 different indicators was extracted. See Table 1 for the final list of indicators.

[Figure 1 about here]

[Table 1 about here]

Table 1 shows that of the 59 indicators, 53 could potentially be assessed using routine data and seven would require primary data collection from patients or professionals. Seventeen of the 59 indicators are, or have previously been included in the QOF. A large proportion of the indicators relevant to primary care are in the physical health domain. Another large sub-set of indicators relate to the process of receiving care, for example, continuity of care, access to services and frequency of contacts.

Table 2 shows the quality of evidence of the included studies from which the indicators were drawn. Four studies were rated as high quality (Cochrane or systematic review, randomised control trial); two as moderate (non-randomised study or unsystematic review); 19 as low quality (expert opinion, uncontrolled studies); and four were of uncertain quality, having been identified from the 'grey' literature (e.g. (non-)government organisations' documents or databases).

Only very few randomised control trials (RCTs) have evaluated quality indicators. Two RCTs were reviewed in Cimo et al <sup>29</sup> producing evidence on the effectiveness of lifestyle interventions for people with type 2 diabetes and schizophrenia or schizoaffective disorder. However, more often, indicators were based on expert consensus or small cross-sectional studies.

Many of the indicators identified were derived from a database of indicators produced by the USA Agency for Healthcare Research and Quality (AHRQ) <sup>24</sup>, and the strength of evidence underpinning the individual indicators is variable.

[Table 2 about here]



## Discussion

### Summary

To our knowledge this is the first attempt to identify potential indicators of quality of primary care for people with SMI in a systematic way. Although we identify over 50 indicators which could potentially be captured and monitored using routine data, crucially, we note that the quality of the available evidence underpinning the indicators is relatively weak.

### Strengths and limitations

The feasibility of collecting data for any set of quality indicators will vary across different healthcare systems. Many countries have insurance or other systems, which routinely collect activity data in primary care. Some indicators are likely to require more effort to collect (e.g. patient questionnaires for perceived continuity of care) and in many cases even routine data collection can prove very challenging. Our study focused specifically on finding indicators which could be monitored at relatively low cost to the healthcare system.

The list of quality indicators identified in this study is much broader and more encompassing than the current list of indicators contained in the QOF SMI domain. However, some of the criticisms inherent to the use of quality metrics would remain even if indicators from this broader list were adopted. These include: measuring only what can be measured (in routine data) at the expense of other measures that matter, e.g. 'softer' measures such as the quality of relationships or the quality of communication<sup>30</sup>; the risk of prioritising some activities at the expense of other non-incentivised activities<sup>31,32</sup>; and the wider impacts of financial incentives and excessive measurement on provider motivation and behaviour<sup>33</sup>. Moreover, there are gaps in the literature and in the indicators identified, meaning that the service user perspective is not well represented. There is also an absence of quality indicators around aspects of the social environment, such as the stability of housing for people with SMI. Although such factors are important and may well influence health outcomes, the extent to which primary care could influence these factors may be very limited and hence it may not be appropriate to hold primary care practitioners responsible for improving quality in these domains. We also acknowledge that there is an extensive literature in related areas of research that will also refer to very similar quality indicators<sup>34</sup>, but the search terms were designed to focus on our specific area of interest, and screened out studies where the focus was broader. Finally, our search excluded non-published indicators and those written in languages other than those listed earlier.

## Implications for Research and/or Practice

In the UK, to be included in the QOF, quality indicators must be supported by NICE evidence-based clinical guideline recommendations or evidence from systematic reviews. This, along with the need to maintain a manageable panel of indicators, explains why the large majority of indicators we identified are not currently part of the QOF. The downside of the QOF approach is that recommendations based on expert consensus are not put forward for inclusion, despite the fact that a body of informed experts would support a *prima facie* rationale for including them. In contrast, the combined views of experts and patients underpin best practice guidance for those commissioning mental health services in the UK, covering many of the domains identified in this review, suggesting scope for a similar approach to be taken with respect to the QOF<sup>35</sup>. The adoption of indicators based on expert and patient consensus must ultimately be supported by evidence on cost-effectiveness, but this also applies to indicators based on higher levels of evidence<sup>36</sup>.

Donabedian's<sup>37</sup> conceptual framework of quality of care suggests indicators can usually be divided into three subcategories: structure, process and outcome measures. To date, the evidence for apparent process improvements under incentive schemes leading to improved patient outcomes is mixed. The vast majority of indicators included in this review relate to processes of care, and whilst aspects of process are highly relevant, especially to patients, it is important to establish whether quality indicators also promote improved health outcomes. If so, there is a case for their inclusion in the QOF and other initiatives aiming to improve the care of people with SMI. For physical conditions, improvements in processes of care in primary care settings have been found to be associated with modest improvements in intermediate outcomes (e.g. cholesterol levels)<sup>38</sup> and quality of life<sup>39</sup>, but associations with patient outcomes such as emergency hospital admission are weaker<sup>40</sup>. For serious mental illness, the evidence is much more limited and suggests that higher provider performance on processes may not be associated with better patient outcomes<sup>17</sup>.

Many of the indicators identified in the study relate to aspects of physical care. People with SMI are at higher risk of physical ill health (particularly diabetes, cardiovascular and respiratory disease), so clearly focusing on these aspects could help reduce the associated excess morbidity and mortality<sup>28</sup>. People with SMI are vulnerable with significant needs for care that may be missed or undertreated, leading to years spent with disabling morbidity and premature mortality. Viron et al<sup>14</sup> emphasised that in the USA, as elsewhere, '*As frontline clinicians, primary care providers have the potential to reduce the health disparities experienced by this population*'. Consideration of the use of a broader set of quality indicators, including those focusing on physical care, may therefore be a positive step. Given the increased risk of diabetes, cardiovascular disease and respiratory disease in this population, ongoing primary care for people with SMI should focus on disease prevention through

tackling obesity and smoking. Similarly, a large set of indicators relate to processes of care, including ongoing contact with relevant services. Targeting comprehensive primary care to people with SMI can also play a crucial role in promoting their engagement with appropriate specialised mental and physical healthcare services, helping them to reach their full potential.

### **Acknowledgements**

The National Institute for Health Services & Delivery Research programme funded this research (project no: 13/54/40). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the HS&DR programme, NIHR, NHS or the Department of Health. We would like to thank the following Study Steering Committee members for their invaluable contributions to this review: David Daniel, Holly Taggart, Ceri Dare, Lauren Aylott and Jane Dunning. We would like to thank Kate Lewis-Light (Centre for Reviews and Dissemination, University of York) who designed and ran the specialist information searches. We would also like to thank Harold Pincus and Constance Stegbauer for sharing their detailed list of quality indicators with us.

**Table 1: Quality of care indicators identified for people with serious mental illness**

Number	Description	Data Source	QOF	AHRQ	References
<b>Co-ordination of Care</b>					
1	Co-ordinated care - identify key worker (social worker or CPN)	Routine Data			41
2	Staff continuity – good communication between staff and infrequent staff changes	Routine Data			42
3	Continuity: CONNECT is a patient questionnaire with 72 items, each rated on a 5-point scale, with 13 scales and 1 single-item indicator (General Coordination - "Overall is your Mental Health treatment well-coordinated?"). Primary Care scales - "How often is psychiatrist in contact with your primary care doctor?" (Never, Rarely, Sometimes, Often, Always).	Primary Data			43
4	Total number of follow-up contacts during treatment episode after initial evaluation	Routine Data			44
<b>Substance Misuse</b>					
5	Patients with SMI who smoke who are offered tobacco counselling / help to stop smoking	Routine Data			24,27
6	Alcohol misuse screening	Routine Data	✓	✓	24
7	Screening for illicit drug use, type, quantity and frequency	Routine Data		✓	24
8	Referral to substance misuse disorder specialty care if appropriate	Routine Data			22
9	HIV screening with co-occurring substance misuse for SMI service users	Routine Data			45
<b>Service Provision and Access to Care</b>					
10	Practice can produce register of all SMI patients	Routine Data	✓		46
11	Service user registration with a primary health organization	Routine Data			22
12	Markers of care recorded: Contact with secondary health services, written care plans, 6-month mental health review, identified care coordinator, evidence of physical examination	Routine Data	✓		47
13	Patients who do not attend the practice for their annual review who are identified and followed up by the practice team	Routine Data	✓	✓	24
14	System contact: Number of patients in contact with the treatment system	Routine Data			22

15	Surveillance to prevent relapse	Routine Data			42
16	Crisis management and out of hours services	Routine Data			43
17	Access to services and range of services	Routine Data			42
18	Family care - record of families living with person with schizophrenia	Primary Data			41
19	Duration of untreated psychosis: Number of recently diagnosed patients	Routine Data			22,48
20	Waiting time between registration and start of treatment	Routine Data			22
<b>Medicines Management</b>					
21	All current medication clearly available at all consultations - known drug dosages, frequencies, history of side effects, review date	Primary Data			41
22	Monitor patients suffering extra pyramidal effects, check compliance	Routine Data			49
23	Assess weight gain, use of concomitant medication	Routine Data	✓		50
24	Use of lithium: Plasma lithium levels monitored regularly	Routine Data	✓		26,51
25	Percentages of bipolar service users prescribed antidepressants and anxiolytics	Routine Data			26,51
26	Proportion of patients who are receiving depot antipsychotics who have appropriate laboratory screening tests	Routine Data		✓	24
27	Patients have their antipsychotic medication reviewed regularly, considering symptoms and side effects: Appropriate referral to specialist	Routine Data			52,53
28	Polypharmacy: Reduce number of patients using more than four psychotropic drugs at the same time	Routine Data			54
29	Monitoring patients with neurological, sexual, sleeping and sedation side effects	Routine Data			55
<b>Mental Health Assessment and Care</b>					
30	Percentage of patients given annual mental health review by GP	Routine Data	✓		56
31	Comprehensive mental status examination and history conducted in patients with a new treatment episode	Routine Data		✓	24,41
32	Referral for specialist mental health assessment	Routine Data			26
33	Comprehensive assessment of co-morbid psychiatric conditions and	Routine Data		✓	24

	response to treatment				
34	Reassess severity of symptoms	Routine Data	✓		57
35	Examined for duration of untreated psychosis	Primary Data			48
36	Delayed diagnosis	Primary Data			58
37	Informal carer contacts	Primary Data			42
38	Information on employment status	Primary Data			41
<b>Physical Health Assessment and Care</b>					
39	Diabetes monitoring for people with diabetes and schizophrenia	Routine Data		✓	24
40	Diabetes and cholesterol monitoring for people with schizophrenia and diabetes	Routine Data		✓	24
41	Diabetes screening for people who are using antipsychotic medications	Routine Data		✓	24
42	Blood pressure screening for patients with diabetes	Routine Data	✓	✓	24,59-62
43	Weight management / BMI monitoring	Routine Data	✓	✓	24,59-62
44	Proportion with increased BMI / abdominal waistline	Routine Data	✓	✓	24,59-62
45	Patients with diabetes who received education about diabetes, nutrition, cooking, physical activity, or exercise	Routine Data		✓	24
46	Counselling on physical activity and / or nutrition for those with documented elevated BMI	Routine Data	✓	✓	24
47	Retinal exam for SMI patients who have diabetes	Routine Data		✓	24
48	Foot exam for SMI patients who have diabetes	Routine Data		✓	24
49	Hypertension counselling: Patients with hypertension who received education services related to hypertension, nutrition, cooking, physical activity, or exercise	Routine Data		✓	24
50	Hypertension: Recording and monitoring patients with hypertension and high blood cholesterol (LDL)	Routine Data	✓	✓	24,59-62
51	Breast cancer screening for women	Routine Data		✓	24
52	Colorectal cancer screening	Routine Data		✓	24
53	Proportion patients who have an increased blood pressure	Routine Data	✓	✓	24,59-62
54	Proportion of patients who have an	Routine	✓	✓	24

	increased blood glucose level	Data			
55	Proportion of patients who have low levels of glycosylated haemoglobin	Routine Data	✓	✓	24
56	Proportion of patients who have increased level of blood lipids	Routine Data			21
57	Comprehensive physical health assessment with appropriate advice	Routine Data	✓		57
58	Patients with diabetes who received psychoeducation related to weight (BMI), diabetes (blood glucose levels)	Routine Data			29
59	Medical attention for nephropathy	Routine Data			63

Note: QOF = UK Quality Outcomes Framework; AHRQ = Agency for Healthcare Research & Quality; BMI = Body Mass Index; LDL = Low-density lipoprotein; GP = General practitioner; CPN = Community psychiatric nurse; SMI = Serious mental illness

**Table 2: Quality of evidence of studies identifying quality of care indicators for people with serious mental illness**


Study	Description of Study	Strength of Evidence*
Parameswaran, Spaeth-Rublee, Pincus <sup>22</sup>	656 measures of quality of mental health care identified in earlier work are rated in importance, validity and feasibility using a modified Delphi process.	3
National Institute for Health and Care Excellence (NICE) <sup>26</sup>	NICE treatment guidelines for bipolar disorder.	4
National Institute for Health and Care Excellence (NICE) <sup>27</sup>	NICE treatment guidelines for schizophrenia.	4
Agency for Healthcare Research and Quality (AHRQ) <sup>24</sup>	The Agency for Healthcare Research and Quality provides a database of quality indicators that was used during the grey literature search.	4
Lester, Tritter, Sorohan <sup>46</sup>	Focus groups with patients, GPs and nurses were conducted to explore how to improve care in cases of acute mental health crises.	3
Sweeney, Rose, Clement, Jichi, Jones, Burns, Catty, McLaren, Wykes <sup>42</sup>	Structured interviews were conducted with 167 individuals suffering from psychoses to establish a concept of service user-defined continuity of care.	3
Ware, Dickey, Tugenberg, McHorney <sup>43</sup>	This study reports on the field testing of an interview based measure of continuity of care.	3
Cerimele, Chan, Chwastiak, Avery, Katon, Unützer <sup>44</sup>	Narrative description of 740 bipolar primary care patients who participated in a mental health integration program (MHIP). Quality of care outcomes were derived from patient disease registry.	3
Pincus, Spaeth-Rublee, Watkins <sup>57</sup>	Discussion on the barriers to measuring quality of care in the mental health arena combined with a short list of potential quality measures.	3
Holden <sup>41</sup>	This study audited 16 GPs on their care for 266 schizophrenia patients and observed that the audit lead to improved recording of a range of quality indicators.	3
Swartz, MacGregor <sup>45</sup>	The authors of this paper argue that in South Africa the role of mental health nurses has been altered to focus on violence, substance misuse and HIV/AIDS and should be refocused on psychiatry care in the primary care setting.	3
Ruud <sup>48</sup>	The author summarizes the literature on quality of care in mental health services in Norway for the years 2008-2009.	3
Highet, McNair, Thompson, Davenport, Hickie <sup>58</sup>	Interviews with 49 bipolar patients to describe experience in primary care in Australia. Eight themes for improvement of the primary care experience are outlined.	3
Lader <sup>49</sup>	Expert review of the standards of care in schizophrenia to reduce side-effects whilst achieving best treatment outcomes.	3
Haro, Salvador-Carulla <sup>50</sup>	Observational study following eleven thousand patients who were on or changing antipsychotic medication to	2



	determine the best course of treatment with respect to symptoms, quality of life, social functioning and other outcomes.	
Caughey, Ellett, Wong <sup>51</sup>	Development, expert review, and assessment of the evidence base for and validity of medication-related indicators of potentially preventable hospitalisations.	3
Busch, Lehman, Goldman, Frank <sup>52</sup>	Observational study examining trends in four measures of quality over time in the US.	2
Young, Sullivan, Burnam, Brook <sup>53</sup>	Uncontrolled study looking at differences in quality of care as variations from national guidelines.	3
Nayrouz, Ploumaki, Farooq, Stock, Lim <sup>54</sup>	Evaluation of an integrated care approach between primary care and community care focused on SMI patients.	3
McCullagh, Morley, Dodwell <sup>47</sup>	This observational study looks at urban vs rural differences in quality of care for psychoses as well as the difference in quality of care conditional on contacts with secondary care.	3
Rodgers, Black, Stobbart, Foster <sup>56</sup>	Audit of quality of care in 822 Scottish patients with schizophrenia.	3
Osborn, Nazareth, Wright, King <sup>59</sup>	Randomised trial to evaluate the impact of a nurse-led treatment to improve screening for CVD in the SMI population.	1
Yeomans, Dale, Beedle <sup>60</sup>	Evaluation of a computer-based physical health screening template versus NICE guidelines for the SMI population.	3
Mitchell, Delaffon, Lord <sup>61</sup>	A systematic review and meta-analysis of screening practices with respect to metabolic risks for psychosis patients.	1
Roberts, Roalfe, Wilson, Lester <sup>62</sup>	A retrospective view of case notes in 22 GP practices to determine whether patients with schizophrenia receive equitable physical health care.	3
Mainz, Hansen, Palshof, Bartels <sup>55</sup>	Description of the Danish National Indicator Project, which intends to document and advance quality of care.	3
Druss, Zhao, Cummings, Shim, Rust, Marcus <sup>63</sup>	The study compared diabetes performance measures in US Medicaid enrollees with and without mental comorbidity.	2

\*Quality of evidence <sup>25</sup> is categorised as (1) High – Cochrane or systematic review, randomised control trial; (2) Moderate – non-randomised control study or unsystematic review; (3) Low – expert opinion, uncontrolled studies; (4) Not applicable – measure was extracted from grey literature e.g. (non-)government organisations’ documents or databases

**Figure 1: PRISMA <sup>58</sup> Flow Diagram for systematic review of quality of care indicators for patients with serious mental illness**



## References

1. World Health Organization, ed The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organisation; 1992.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). Arlington, Virginia: APA; 2014.
3. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. *The British Journal of Psychiatry*. 2001;178(6):506-517.
4. Murray CJ, Richards MA, Newton JN, et al. UK health performance: findings of the Global Burden of Disease Study 2010. *The Lancet*. 2013;381(9871):997-1020.
5. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. *Archives of general psychiatry*. 2007;64(2):242-249.
6. Miller BJ, Paschall III CB, Svendsen DP. Mortality and medical comorbidity among patients with serious mental illness. *Mortality*. 2008;6(2).
7. Wahlbeck K, Westman J, Nordentoft M, Gissler M, Laursen TM. Outcomes of Nordic mental health systems: life expectancy of patients with mental disorders. *The British Journal of Psychiatry*. 2011;199(6):453-458.
8. Harris M. General practice recruitment for schizophrenia prevention studies. *Aust N Z J Psychiatry*. 2000;34 Suppl:S137-139; discussion S140-134.
9. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet*. 2013;380(9859):2163-2196.
10. Layard R. How Mental Illness Loses Out in the NHS A report by The Centre for Economic Performance's Mental Health Policy Group. Centre for Economic Performance, LSE;2012.
11. Reilly S, Planner C, Hann M, Reeves D, Nazareth I, Lester H. The role of primary care in service provision for people with severe mental illness in the United Kingdom. *PloS one*. 2012;7(5):e36468.
12. Kai J, Crosland A, Drinkwater C. Prevalence of enduring and disabling mental illness in the inner city. *Br J Gen Pract*. 2000;50(461):992-994.
13. Lang FH, Johnstone E, Murray G. Service provision for people with schizophrenia. II. Role of the general practitioner. *The British Journal of Psychiatry*. 1997;171(2):165-168.
14. Viron M, Baggett T, Hill M, Freudenreich O. Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population. *American Journal of Medicine*. 2012;125(3):223-230.
15. Organization WH. The world health report 2003: shaping the future. World Health Organization; 2003.
16. Organization WH. WHO QualityRights tool kit: assessing and improving quality and human rights in mental health and social care facilities. World Health Organization; 2012.
17. Gutacker N, Mason AR, Kendrick T, et al. Does the quality and outcomes framework reduce psychiatric admissions in people with serious mental illness? A regression analysis. *BMJ open*. 2015;5(4):e007342.
18. Smith P. On the unintended consequences of publishing performance data in the public sector. *International journal of public administration*. 1995;18(2-3):277-310.
19. Doran T, Kontopantelis E, Valderas JM, et al. Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK Quality and Outcomes Framework. *Bmj*. 2011;342:d3590.
20. Eggleston K. Multitasking and mixed systems for provider payment. *Journal of Health Economics*. 2005;24(1):211-223.

21. Stegbauer C, Szecsenyi J, Bramesfeld A. Studien zur Evaluation ambulanter psychiatrischer Versorgung: Werden die Prioritäten psychisch kranker Menschen berücksichtigt? *Psychiat Prax.* (EFirst).
22. Parameswaran SG, Spaeth-Ruble B, Pincus HA. Measuring the quality of mental health care: Consensus perspectives from selected industrialized countries. *Administration and Policy in Mental Health and Mental Health Services Research.* 2014;1-8.
23. Großimlinghaus I, Falkai P, Gaebel W, et al. Entwicklungsprozess der DGPPN-Qualitätsindikatoren. *Der Nervenarzt.* 2013;84(3):350-365.
24. Agency for Healthcare Research and Quality (AHRQ). AHRQ - Quality Indicators. 2016; [www.qualityindicators.ahrq.gov](http://www.qualityindicators.ahrq.gov).
25. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. *Journal of Clinical Epidemiology.* 2011;64(4):401-406.
26. National Institute for Health and Care Excellence (NICE). Bipolar disorder: assessment and management. 2014.
27. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults. 2015.
28. Hoang U, Goldacre MJ, Stewart R. Avoidable mortality in people with schizophrenia or bipolar disorder in England. *Acta Psychiatrica Scandinavica.* 2013;127(3):195-201.
29. Cimo A, Stergiopoulos E, Cheng C, Bonato S, Dewa CS. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: a systematic review (Structured abstract). *BMC Psychiatry.* 2012;12(1):24. <http://onlinelibrary.wiley.com/doi/10.1186/1471-2288-12-24>
30. McDonald R, Harrison S, Checkland K, Campbell S, Roland M. Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study. *BMJ.* 2007;334:1357-62.
31. Doran T, Kontopantelis E, Valderas J, Campbell S, Roland M, Salisbury C, Reeves D. Effect of Financial Incentives on Incentivised and Non-Incentivised Clinical Activities: Longitudinal Analysis of Data from the UK Quality and Outcomes Framework. *BMJ.* 2011;342(1):d3590.
32. Kreif N, Grieve R, Hangartner D, Turner A, Nikolova S, Sutton M. Examination of the synthetic control method for evaluating health policies with multiple treated units. *Health Econ.* 2015;24(11):1300–17.
33. Doran T. Incentivising improvements in health care delivery: a response to Adam Oliver. *Health Economics, Policy and Law.* 2015;10:351-356.
34. Byng R, Jones R, Leese M, Hamilton B, McCrone P, Craig T. Exploratory randomised controlled trial of shared care development for long-term mental illness. *Br J Gen Pract.* 2004; 54:259-266.
35. Joint Commissioning Panel for Mental Health. Guidance for commissioners of primary mental health care services. *JCPMH;* 2013:1-20.
36. Doran T, Maurer KA, Ryan AM. Impact of provider incentives on quality and value of health care. *Annual Review of Public Health.* 2017;38:7.17.
37. Donabedian A. The quality of care: How can it be assessed? *Jama.* 1988;260(12):1743-1748.
38. Ryan AM, Doran T. The effect of improving processes of care on patient outcomes: evidence from the United Kingdom's quality and outcomes framework. *Medical care.* 2012;50(3):191-199.
39. Kahn KL, Tisnado DM, Adams JL, et al. Does Ambulatory Process of Care Predict Health-Related Quality of Life Outcomes for Patients with Chronic Disease? *Health services research.* 2007;42(1p1):63-83.
40. Flodgren G, Eccles MP, Shepperd S, Scott A, Parmelli E, Beyer FR. An overview of reviews evaluating the effectiveness of financial incentives in changing healthcare professional behaviours and patient outcomes. *Cochrane Database Syst Rev.* 2011;7(7).

41. Holden J. An audit of the care of 266 patients with schizophrenia in 16 general practices. *Irish Journal of Psychological Medicine*. 1998;15(2):61-63.
42. Sweeney A, Rose D, Clement S, et al. Understanding service user-defined continuity of care and its relationship to health and social measures: a cross-sectional study. *BMC Health Serv Res*. 2012;12:145.
43. Ware NC, Dickey B, Tugenberg T, McHorney CA. CONNECT: a measure of continuity of care in mental health services. *Ment Health Serv Res*. 2003;5(4):209-221.
44. Cerimele JM, Chan Y-F, Chwastiak LA, Avery M, Katon W, Unützer J. Bipolar disorder in primary care: clinical characteristics of 740 primary care patients with bipolar disorder. *Psychiatric Services*. 2014.
45. Swartz L, MacGregor H. Integrating services, marginalizing patients: Psychiatric patients and primary health care in South Africa. *Transcultural Psychiatry*. 2002;39(2):155-172.
46. Lester H, Tritter JQ, Soroohan H. Managing crisis: the role of primary care for people with serious mental illness. *Fam Med*. 2004;36(1):28-34.
47. McCullagh M, Morley S, Dodwell D. A systematic, confidential approach to improving community care for patients with non-affective psychosis. *Primary Care Psychiatry*. 2003;8(4):127-130.
48. Ruud T. Mental health quality and outcome measurement and improvement in Norway. *Curr Opin Psychiatry*. 2009;22(6):631-635.
49. Lader M. Consensus statements on standards of care in schizophrenia. *Primary Care Psychiatry*. 1997;3(3):145-149.
50. Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) Study: Implications for the Treatment of Schizophrenia. *CNS Drugs*. 2006;20(4):293-301.
51. Caughey G, Ellett L, Wong T. Development of evidence-based Australian medication-related indicators of potentially preventable hospitalisations: a modified RAND appropriateness method *BMJ Open*. 2014.
52. Busch AB, Lehman AF, Goldman H, Frank RG. Changes over time and disparities in schizophrenia treatment quality. *Medical Care*. 2009;47(2):199-207.
53. Young AS, Sullivan G, Burnam MA, Brook RH. Measuring the quality of outpatient treatment for schizophrenia. *Archives of General Psychiatry*. 1998;55(7):611-617.
54. Nayrouz S, Ploumaki S, Farooq R, Stock D, Lim H. Physical health problems in patients with severe mental illness: Relationship between antipsychotic treatment and physical health. *European Neuropsychopharmacology*. 2011;21:S480-S481.
55. Mainz J, Hansen AM, Palshof T, Bartels PD. National quality measurement using clinical indicators: the Danish National Indicator Project. *Journal of surgical oncology*. 2009;99(8):500-504.
56. Rodgers J, Black G, Stobbert A, Foster J. Audit of primary care of people with schizophrenia (in general practice in Lothian). *Quality in Primary Care*. 2003;11(2):133-140.
57. Pincus HA, Spaeth-Ruble B, Watkins KE. The case for measuring quality in mental health and substance abuse care. *Health Affairs*. 2011;30(4):730-736.
58. Highet NJ, McNair BG, Thompson M, Davenport TA, Hickie IB. Experience with treatment services for people with bipolar disorder. *Med J Aust*. 2004;181(7 Suppl):S47-51.
59. Osborn DP, Nazareth I, Wright CA, King MB. Impact of a nurse-led intervention to improve screening for cardiovascular risk factors in people with severe mental illnesses. Phase-two cluster randomised feasibility trial of community mental health teams. *BMC Health Serv Res*. 2010;10:61.
60. Yeomans D, Dale K, Beedle K. Systematic computerised cardiovascular health screening for people with severe mental illness. *Psychiatr Bull* (2014). 2014;38(6):280-284.
61. Mitchell AJ, Delaffon V, Lord O. Let's get physical: Improving the medical care of people with severe mental illness. *Advances in Psychiatric Treatment*. 2012;18(3):216-225.

62. Roberts L, Roalfe A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. *Fam Pract*. 2007;24(1):34-40.
63. Druss BG, Zhao L, Cummings JR, Shim RS, Rust GS, Marcus SC. Mental comorbidity and quality of diabetes care under Medicaid: a 50-state analysis. *Medical care*. 2012;50(5):428.
64. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of internal medicine*. 2009;151(4):264-269.

## Appendix 1 - Annotated search strategy: (MEDLINE via OVID SP)

- 1 serious mental illness\*.tw. (2037)
  - 2 serious mental disorder\*.tw. (260)
  - 3 serious psychiatric illness\*.tw. (61)
  - 4 serious psychiatric ill-health\*.tw. (0)
  - 5 serious mental ill-health\*.tw. (0)
  - 6 serious psychiatric disorder\*.tw. (130)
  - 7 severe mental illness\*.tw. (2679)
  - 8 severe mental disorder\*.tw. (720)
  - 9 severe mental ill-health\*.tw. (2)
  - 10 severe psychiatric illness\*.tw. (128)
  - 11 severe psychiatric disorder\*.tw. (379)
  - 12 severe psychiatric ill-health\*.tw. (0)
  - 13 major mental disorder\*.tw. (288)
  - 14 major mental illness\*.tw. (350)
  - 15 major psychiatric illness\*.tw. (151)
  - 16 major psychiatric ill-health\*.tw. (0)
  - 17 major psychiatric disorder\*.tw. (730)
  - 18 major mental ill-health\*.tw. (0)
  - 19 schizophrenia/ or schizophrenia, catatonic/ or schizophrenia, disorganized/ or schizophrenia, paranoid/ or shared paranoid disorder/ (86432)
  - 20 (Schizophrenia\* or schizophrenic or dementia praecox).tw. (90771)
  - 21 Schizotypal Personality Disorder/ (2217)
  - 22 (disorder\* adj2 schizotypal).tw. (702)
  - 23 (disorder\* adj1 delusional).tw. (703)
  - 24 Psychotic Disorders/ (32708)
  - 25 ((psychotic adj2 disorder\*) or (schizoaffective adj2 disorder\*) or psychoses or psychosis or schizophreniform).tw. (38127)
  - 26 bipolar disorder/ or cyclothymic disorder/ (32171)
  - 27 (Bipolar adj2 (disorder\* or depression or depressive or psychosis or psychoses)).tw. (22038)
  - 28 (Manic state\* or mania).tw. (8053)
  - 29 (Manic adj2 (disorder\* or depression or depressive or psychosis or psychoses)).tw. (4445)
  - 30 (cyclothymic disorder\* or cyclothymic personalities or cyclothymic personality).tw. (95)
  - 31 or/1-30 (179930)
- Line 31 captures terms for serious mental illness**
- 32 exp Primary Health Care/ (82203)
  - 33 general practitioners/ or physicians, family/ or physicians, primary care/ (18403)
  - 34 general practice/ or family practice/ (64455)
  - 35 (family adj2 pract\*).tw. (11764)
  - 36 (primary adj2 care).tw. (89376)
  - 37 (general adj2 pract\*).tw. (69034)
  - 38 (family adj2 physician\*).tw. (12969)
  - 39 Ambulatory Care/ (36401)
  - 40 or/32-39 (268786)
- Line 40 captures terms for primary care**
- 41 Quality Indicators, Health Care/ (10737)
  - 42 (quality adj2 indicat\*).tw. (6747)
  - 43 (quality adj2 measure\*).tw. (12491)
  - 44 (quality adj2 criteria).tw. (3829)
  - 45 (performance adj2 indicat\*).tw. (4837)
  - 46 (performance adj2 measure\*).tw. (14194)
  - 47 (performance adj2 criteria).tw. (1367)

48 (incentive\* adj3 scheme\*).tw. (207)  
49 (incentive\* adj3 assess\*).tw. (96)  
50 (incentive\* adj3 measure\*).tw. (152)  
51 (incentive\* adj3 outcome\*).tw. (96)  
52 "Standard of Care"/ (1049)  
53 (standard\* adj2 care).tw. (25676)  
54 (standard\* adj2 healthcare).tw. (400)  
55 "Quality of Health Care"/ (58460)  
56 (quality adj2 (healthcare or care)).tw.  
(39007)  
57 patient outcome assessment/ (934)  
58 (patient adj2 outcome assessment\*).tw.  
(70)  
59 (patient adj2 outcome measure\*).tw.  
(2492)  
60 proms.tw. (263)

61 patient satisfaction/ or patient  
preference/ (63756)  
62 (patient\* adj2 satisfaction).tw. (26024)  
63 (patient\* adj2 experience\*).tw. (59692)  
64 (patient\* adj2 preference\*).tw. (8103)  
65 quality.tw. (594390)  
66 or/41-65 (782974)

**Line 66 captures terms for quality indicators**

67 31 and 40 and 66 (551)

**Line 67 identifies records that contain at least one term for serious mental illness, and at least one term for primary care and at least one term for quality indicators**

68 limit 67 to yr="1990 -Current" (537)

**Line 68 applies the date limit**



**Appendix 2: PRISMA Checklist <sup>64</sup> for systematic review of quality of care indicators for patients with serious mental illness**

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	3
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	N/A
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	N/A
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	16
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	N/A
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	N/A

Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	N/A
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	N/A
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	N/A
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	5
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	N/A
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	N/A
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	N/A
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	5
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	6
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	6
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	1